Added to YB: 2026-02-26
Pitch date: 2026-02-23
TBPH [neutral]
Theravance Biopharma, Inc.
-14.58%
current return
Author Info
No bio for this author
Company Info
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
Market Cap
$687.6M
Pitch Price
$19.14
Price Target
N/A
Dividend
N/A
EV/EBITDA
-12.82
P/E
23.38
EV/Sales
4.97
Sector
Pharmaceuticals
Category
special_situation
Further thoughts and corrections for $TBPH
TBPH (update): Liquidation floor raised to $21.43/share ($1.093B: $393M cash+milestones, $150M Trelegy tail, $550M YUPELRI+tax shield). YUPELRI patents stronger than consensus (generic settlements to 2039 vs 2035). CYPRESS 90% powered for 1-point OHSA improvement. Shibao atomoxetine study has stat errors; recalc shows sig results on endpoints, positive for ampreloxetine. Results expected Feb 25 earnings.
Read full article (6 min)